making medicines better™ feel

NASDAQ: ATRS



Third Quarter 2019 Operating and Financial Results Conference Call November 5, 2019





Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; market acceptance of Teva's generic epinephrine auto-injector product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.'s Makena[®] subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions; market acceptance and revenue from the Makena[®] subcutaneous auto injector product; Teva's ability to successfully commercialize VIBEX[®] Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP^{*}; the timing and results of the Company's or its partners' research projects or clinical trials of product candidates in development including projects with Teva and Pfizer and our proprietary projects ATRS-1701 and ectopic pregnancy; actions by the FDA or other regulatory agencies with the respect to the Company's products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; achievement of the Company's 2019 updated revenue guidance; successful completion of the transaction with Ferring International Center, S.A; the Company's ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation with Hercules Capital; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's most recently filed Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this presentation. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

©2019 Copyright Antares Pharma, Inc. All Rights Reserved.



	hird Quarter 2019 Inancial Results Cor	nference Call		
Agenda				
Introductions		Jack Howarth		
Third Quarter 2019 Recap/Comm	ercial Business Update	Bob Apple		
Third Quarter Financial Results		Fred Powell		
Closing Remarks		Bob Apple		
Q&A		All		
antares	making medicines better* feel	3		

NASDAQ: ATRS Q319 Significant Financial Achievements

Record quarterly revenue of \$34.3 million – a 92% increase vs. Q318

\$24.7 million in product revenue – a 113% increase as compared to the same period one year ago

- Commercialized Proprietary Products: XYOSTED[®], OTREXUP[®] \$11.5M
- Partnered Products: Epi, Makena[®], Teriparatide, Sumatriptan, Needle Free \$13.2M
- Royalty Revenue \$8.4M a 126% increase vs. Q318 and a 51% sequential increase over Q219




XYOSTED[®] Monthly TRx Growth

- More than 35,000 XYOSTED TRx's to date written by 3,500 different physicians
- More than 12,000 patients prescribed XYOSTED since launch
- Q319 TRx's increased 73% sequentially vs. Q219

NASDAQ: ATRS

As of 10/1/19 – ~70% of all commercial lives covered



Social Media Creative: Facebook & Instagram NASDAQ: ATRS

Facebook

						1000000 x 10				
xvOSTED (bestosterone enanthate) injection 1 mockup			Internet XYOSTED (bestoaterone enanthate) injection 1 mockup				Sponsord · @			
Please see the full Presorbing Information, including Board Warning, and Medication Galet at [bit/b] auPOINTANT SAFETY INFORMATION What is the most important safety information I should know about XYIOSTEDP XYIOSTEDP XXIII AND A A			Please see the full Preaching Information, Including Board Warning, and Medication Guide at [cit], [INPORTIANT SAFETY NFORMATION What is the most important safety information I should know about XY00TED?				Please see the full Prescribing Information, including Boxed Warning, Medication Gode at [sh1/b] IMPORTANT SAFETY NFCRMATION What is the most important safety information I should know about XnOSTED.			
which can increase your ri	sk of having a heart I due to a heart atta	ok or stroke. Your risk may	which can in increase you	ure Increases - XYOSTED screase your risk of having ar risk of death due to a he 'you have already had a h	a heart attack or str sart attack or stroke.	toke and can Your risk may	which c increase	en increase your r your risk of deat	I – XYOSTED can increa risk of having a heart at th due to a heart attack eady had a heart attack	tack or stroke and ca or stroke. Your risk n
		S. THAT		L	N TO A DOCTOR ABOAT	XYOSTED	TACK T	A DOCTOR ABOUT	XYOSTED	
FOR A MASSLE F LOW T TREATME SHIT TO WORK WELK AFTER WE	нт		<	XYO (ERR	INSTEAD		and the second se		CLICK FO SU CO-FR NOW	
LOW IT TREATME ISSUE TO WORK WEEK AFTER WE	NT CNC -		A' anclinges in solar traises Belance of	XYO	STED INSTEAD	di originality	05	TED	\$0 CO-PR NOW	
LOW T TREATME BUILT TO WORK WELK APTELE WE	NT CNC -	And the second s	in solutinates		STED INSTEAD		05		SI CO-PA NOW	
LOW TTREATME BUILT TO WORK WEEK AFTER WE	NT CNC -	TOTAL Personal Annual A	in solutinates			CL 10 2 Validations Ministration Ministratio	05		SU CO-PS NOW Youth rectine and Profit Kit paradoses and for profits associate and anongenesis topposes.	

Instant XYOSTED (Instatuses enanthate) injection Boowend - @ Boowend - @ Plesse see the full Precorbing Information, Including Boxed Warning, and Medication Guide at [bit/] Medication Guide at [bit/] WPORTANT SAFETY REFORMATION Medication Medication	Inter: XYOSTED (testosterere enanthate) injection Socraced - O Please see the full Prescribing Information, Including Boxed Warring, and Medication Guide at [bit/y] IMPORTANT SAFETY INFORMATION
What is the most important safety information I should know about	What is the most important safety information I should know about
XYOSTED?	XYOSTED?
Blood Pressure Increases - XYOSTED can increase your blood pressure,	Bood Pressure Increases – XYOSTED can increase your blood pressure,
which can increase your risk of having a heart attack or stroke and can	which can increase your risk of having a heart attack or stroke and can

AYUSIED

Commant

INSTEAD

Lears More

View eligibili

2 Share

Blood Pressure Increases - XYOSTED can increase y which can increase your risk of having a heart attack increase your risk of death due to a heart attack or stroke. Your risk may increase your risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack or stro ... See More be greater if you have already had a heart attack or stro ... See More



Jerning, and

- hode
- I man mi and can or risk may Month

sam More Share

XYOSTED (testosterone enanthate) injection Please see the full Prescribing Information, including Boxed Warning, and Medication Guide at [bit.lv] IMPORTANT SAFETY INFORMATION

What is the most important safety information I should know about XYOSTED?

Blood Pressure Increases - XYOSTED can increase your blood pressure. which can increase your risk of having a heart attack or stroke and can increase your risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack or stro ... See More YOSTED

CLICK FOR

10 CO-PMT

NOW

View eligibility restriction

Connert


USIEU

INSTEAD

Learn Hors

r¹ Like

i apply.



5:05

Instagram

be controlled. XYOSTED may need to be stopped. Your healthcare provider should monitor y pressure while you are being treated with XYDSTED.

XYOSTED is a prescription medicine that contains testosterone. XYDSTED is used to treat adult men who have low or no testosterone due to certain

.

medical conditions

6 Q (Ŧ)




ntares

Learn More

2 Share


NASDAQ: ATRS

Generic EpiPen® Quarterly TRx Prescription Trends



NASDAQ: ATRS

5-year Growth and 2019 Projection NASDAQ: ATRS



8

NASDAQ: ATRS

Third Quarter and Year-to-Date 2019 Financial Results

	Three Mon Sept		Increase		ths Ended t 30	Increase
	2019	2018	(Decrease)	2019	2018	(Decrease)
Total Revenue	\$ 34,306	\$ 17,868	92%	\$ 86,025	\$ 44,733	92%
Cost of Revenue	13,062	7,289	79%	36,449	21,435	70%
Gross Profit	21,244	10,579	101%	49,576	23,298	113%
% Revenues	62%	59%		58%	52%	
Research & Development	2,863	3,191	(10%)	7,744	9,321	(17%)
Selling, General & Administrative	16,385	8,747	87%	46,407	24,866	87%
Total Operating Expenses	19,248	11,938	61%	54,151	34,187	58%
Operating Income/(Loss)	1,996	(1,359)	(247%)	(4,575)	(10,889)	(58%)
Interest Expense	(1,097)	(674)	63%	(2,470)	(1,959)	26%
Other Income (Expense)	144	97	48%	323	199	62%
Net Income/(Loss)	\$ 1,043	\$ (1,936)	154%	\$(6,722)	\$ (12,649)	(47%)
Earnings/(Loss) Per Share	\$ 0.01	\$ (0.01)		\$ (0.04)	\$ (0.08)	
antares	r	naking medicin fe	· · · · · · · · · · · · · · · · · · ·			9

Antares in 2019: "A Transformational Year"

Accomplishments

Updated revenue guidance for 2019

Potential increase of approximately 89% over 2018-reported revenue

Q3 2019 revenue of \$34.3M, a 92% increase vs. Q2 2018

Expanding operational capabilities with new office, laboratory, manufacturing and warehouse space

Executed an amendment to an existing loan to increase available capital by \$25 million for a term loan up to \$50 million

Catalysts

Continued XYOSTED[®] prescription growth and adoption

NASDAQ: ATRS

Continued generic EpiPen® and EpiPen® Jr. prescription growth and adoption

Potential FDA approval and launch of Teva's generic teriparatide (Forteo®)

New proprietary pipeline products

Potential additional, new alliance transactions

Foundation

ares

Identify, develop, and commercialize important rescue and self-injection medicines





Third Quarter 2019 Operating and Financial Results Conference Call

Q & A





making medicines better™ feel



Follow-Up Questions 609-359-3016 Antares Investor Relations





NASDAQ: ATRS